다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Eterna Therapeutics Inc (ERNA)
Eterna Therapeutics Inc (ERNA) 뉴스

ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ERNA

1 2 3 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	06:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/10	21:00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/08	22:31	GlobeNewswire Inc.	Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/07	21:00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/05/07	21:00	GlobeNewswire Inc.	Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/20	22:30	GlobeNewswire Inc.	Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/17	07:30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/02/16	21:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/31	21:05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/25	06:15	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/23	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/20	06:16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/20	00:31	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/17	06:16	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/13	06:49	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07:01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	07:01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2024/01/04	06:15	GlobeNewswire Inc.	Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/23	02:05	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	06:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	06:15	GlobeNewswire Inc.	Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	05:24	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/21	00:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/19	11:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/15	08:56	GlobeNewswire Inc.	Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/12/15	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/17	06:16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/14	07:30	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ERNA	Eterna Therapeutics Inc
2023/11/13	22:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ERNA	Eterna Therapeutics Inc

검색 관련기사 보기:NASDAQ:ERNA

1 2 3 다음 >>

JP Morgan Chase

American Express

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

US Dollar vs Yen

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관